ArticleCurrent medicinal chemistry2026
Investigating the Mechanisms of Pazopanib-induced Hepatotoxicity: Insights from Network Toxicology, Microarray Analysis, and Machine Learning.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPazopanib is an oral multi-kinase inhibitor that is effective in treating various tumors. However, it is commonly associated with hepatotoxicity, which can interrupt treatments and cause delays, thereby increasing the risk of tumor progression. The mechanisms underlying pazopanib-induced hepatotoxicity remain unclear and limit the development of effective preventive strategies. This study aimed to identify the core genes and investigate the mechanisms associated with pazopanib-induced hepatotoxicity by integrating network toxicology, microarray analysis, and machine learning.
methodsPotential pazopanib targets were identified from multiple databases. Differential expression analysis was conducted using microarray data from hepatocyte-like cells treated with pazopanib and from matched control samples. Genes that overlapped between pazopanib targets and differentially expressed genes (DEGs) were considered potential pathogenic targets for hepatotoxicity. Multiple machine learning algorithms were employed for gene selection to improve accuracy and predictive capability. Molecular docking was used to evaluate the binding affinity of pazopanib to core proteins. Functional enrichment analysis was conducted to elucidate the potential toxic mechanisms.
resultsOur analysis identified 162 target genes for pazopanib and 291 DEGs, revealing seven shared genes as potential pathogenic targets for pazopanib-induced hepatotoxicity. Using machine learning, we further detected four core target genes: CYP1A1, DDR2, FGF1, and PLK4. Molecular docking confirmed that pazopanib stably bound to these core proteins. Functional enrichment analysis indicated that the hepatotoxicity associated with pazopanib may involve p53 signaling, impaired cell cycle, and immune modulation.
conclusionThis study enhances our understanding of the molecular mechanisms underlying pazopanib-induced hepatotoxicity, which is essential for developing protective strategies and therapeutic interventions. By integrating network toxicology, microarray analysis, and machine learning, this study provides a comprehensive framework for investigating the complex toxicological processes of specific compounds and offers insights that could improve the clinical applications and regulatory safety of targeted therapies.
Indexed as
Identifiers
40417760What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.